Cargando…
HTLV-1 epigenetic modification of the FoxP3 TSDR in HAM/TSP decreases the functional proliferative suppression of Tregs
Autores principales: | Anderson, Monique R, Akahata, Yoshimi, Massoud, Raya, Ngouth, Nyater, Oh, Unsong, Jacobson, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044226/ http://dx.doi.org/10.1186/1742-4690-11-S1-O34 |
Ejemplares similares
-
Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2021) -
Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP
por: Enose‐Akahata, Yoshimi, et al.
Publicado: (2019) -
Correlation of increased CXCL13 with intrathecal humoral immune responses to HTLV-1 in CSF of patients with HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2014) -
Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2017) -
Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2019)